sameAs
A direct interaction with NEDD1 regulates gamma-tubulin recruitment to the centrosomeHtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteinsDifferential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic functionAsymmetric recruitment of cIAPs by TRAF2The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3- and caspase 9-interacting sitesProapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activityThe structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activitySolution structure of a baculoviral inhibitor of apoptosis (IAP) repeatStructural insights into the degradation of Mcl-1 induced by BH3 domainsStructure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in transStructural plasticity underpins promiscuous binding of the prosurvival protein A1Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1Structures of the cIAP2 RING domain reveal conformational changes associated with ubiquitin-conjugating enzyme (E2) recruitmentSolution structure of Psb27 from cyanobacterial photosystem IIThe structure of Boo/Diva reveals a divergent Bcl-2 proteinRING domain dimerization is essential for RNF4 functionCARD-mediated autoinhibition of cIAP1's E3 ligase activity suppresses cell proliferation and migrationRegulation of ubiquitin transfer by XIAP, a dimeric RING E3 ligaseStructure of the bacterial type II NADH dehydrogenase: a monotopic membrane protein with an essential role in energy generationSecondary ubiquitin-RING docking enhances Arkadia and Ark2C E3 ligase activityStructure and Function of the RING Domains of RNF20 and RNF40, Dimeric E3 Ligases that Monoubiquitylate Histone H2BMutation of arginine 121 in lactoferrin destabilizes iron binding by disruption of anion binding: crystal structures of R121S and R121E mutantsBim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targetsIntrinsically disordered proteins in bcl-2 regulated apoptosis.Direct inhibition of caspase 3 is dispensable for the anti-apoptotic activity of XIAP.Tumor necrosis factor (TNF) signaling, but not TWEAK (TNF-like weak inducer of apoptosis)-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, requires cIAP1 RING dimerization and E2 binding.Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundanceThe ubiquitin-associated domain of cellular inhibitor of apoptosis proteins facilitates ubiquitylationThe Bcl-2-regulated apoptotic pathway.Regulation of apoptosis: uncovering the binding determinants.Assembling the building blocks: structure and function of inhibitor of apoptosis proteins.TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis.RINGs hold the key to ubiquitin transfer.Use of E2~ubiquitin conjugates for the characterization of ubiquitin transfer by RING E3 ligases such as the inhibitor of apoptosis proteins.IAPs: Modular regulators of cell signalling.The molecular basis of lysine 48 ubiquitin chain synthesis by Ube2K.Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands.Tissue distribution of Diablo/Smac revealed by monoclonal antibodies.Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization.The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
P50
Q21142631-6D553EA0-FC9C-4C04-89EC-8ACF6D4E5005Q24291802-15776F55-D695-4D8F-80DF-2BCF712BD80DQ24293924-08B03B5E-2AE7-4D7C-910E-9BF4A7571889Q24310283-312C291B-3EA6-4463-891F-44965D067812Q24673550-BB911771-95F1-437A-B5DB-BE4554F3E210Q24675444-864F15D1-4E7C-4BC5-B5DE-5C9ACB615C9CQ24683846-76F28356-3032-4B32-970F-1383FDA5052CQ27619017-A5892FC4-4669-48E3-A34B-D860ACD016A9Q27644256-5737FE44-E3FF-4ABD-B558-A534BBE5BF7AQ27649717-958C7CFB-6887-4BE3-A946-C6180B7D11C8Q27650558-B1FC033A-AC70-43A7-9291-0CB2DC8BDF05Q27651003-279C6090-35FF-4F59-9FE4-31493630CFF9Q27652077-147757E5-6BB9-492D-8C79-8CA865108C12Q27657118-C8D72012-17C2-4D7B-938F-A4FA5414357DQ27661480-441D5DF1-D6D5-4289-B8B3-F9342FEBCF4DQ27663855-B73A4167-6524-4332-9D49-29079DDF00E5Q27667747-997E2384-0CAD-4A58-965B-C38A03008345Q27683623-7BFFF92D-89ED-4FF2-AEEB-F57176B26A6BQ27688947-C9E989C3-FE35-4642-9933-6E0484D24129Q27703126-637F02EE-CAC3-49BC-9772-15081DCE1D82Q27727753-94761C73-703E-4809-A119-A10013C2AA2BQ27733942-116AD437-8FAC-48F8-8C6C-4266F4BC658AQ28910218-B0A2A762-E748-4913-A592-416EA6ADF94EQ30389323-DE94759D-3867-41F3-86F7-000D1BF5CF5FQ30992809-45CEE6CE-AECA-4613-B847-A4BC889B45A5Q33885155-DD92C152-1765-425C-969E-FC653565B02BQ34132152-74DF8FD8-49C0-4CA8-8FC0-061D744559AEQ34170749-E7CEC7F0-AB61-40E4-98CD-24F8BBBE8A5EQ35218049-1764D340-43EC-4FA1-837C-1BD0B12586E5Q36303190-769D9C59-5FAE-4710-A052-2BAA92CEFF89Q37448134-A4C3F13F-68DD-4A51-9286-FFF94226F955Q37467736-CF80726E-2CA6-4D98-88EC-FCEBD01428C2Q37966409-35BF8304-77BD-4468-9292-20E8746BE7C5Q38234375-67D49D94-93F5-4383-8ABE-32A47C90A225Q38301272-1150EEFA-66BB-4C14-8BB0-EE5533FBC698Q40291384-42DF5F1A-734D-4460-ACCA-4BA466D67049Q40490346-BBA776B8-FDEE-45C4-8D7C-7FBB2FE30E60Q40726060-EA0013D4-E8BE-4DBF-A215-F11D11F436F4Q41905427-FA9E18EA-6D23-42EE-A4F3-BAA6E33ADEEAQ42064781-7A0222ED-EE01-43D7-9719-4BF772640F0A
P50
description
New Zealand biochemist
@en
biochemicus
@nl
hulumtuese
@sq
հետազոտող
@hy
name
Catherine L Day
@es
Catherine L Day
@nl
Catherine L. Day
@en
Catherine L. Day
@sq
type
label
Catherine L Day
@es
Catherine L Day
@nl
Catherine L. Day
@en
Catherine L. Day
@sq
altLabel
Catherine Day
@en
prefLabel
Catherine L Day
@es
Catherine L Day
@nl
Catherine L. Day
@en
Catherine L. Day
@sq
P1153
7201846634
P21
P31
P496
0000-0003-1571-4367